Silver Oak Securities Incorporated Purchases 1,491 Shares of Stryker Co. (NYSE:SYK)

Silver Oak Securities Incorporated boosted its position in shares of Stryker Co. (NYSE:SYK) by 151.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,475 shares of the medical technology company’s stock after acquiring an additional 1,491 shares during the quarter. Silver Oak Securities Incorporated’s holdings in Stryker were worth $741,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in SYK. Linden Thomas Advisory Services LLC boosted its holdings in Stryker by 6.9% during the 3rd quarter. Linden Thomas Advisory Services LLC now owns 2,915 shares of the medical technology company’s stock valued at $797,000 after acquiring an additional 188 shares during the period. Avestar Capital LLC boosted its stake in shares of Stryker by 17.0% during the third quarter. Avestar Capital LLC now owns 1,116 shares of the medical technology company’s stock valued at $305,000 after purchasing an additional 162 shares during the period. Brookstone Capital Management grew its holdings in shares of Stryker by 6.9% in the third quarter. Brookstone Capital Management now owns 8,022 shares of the medical technology company’s stock worth $2,153,000 after purchasing an additional 521 shares during the last quarter. PDS Planning Inc increased its stake in Stryker by 3.0% in the 3rd quarter. PDS Planning Inc now owns 1,318 shares of the medical technology company’s stock worth $360,000 after buying an additional 38 shares during the period. Finally, Copeland Capital Management LLC lifted its holdings in Stryker by 16.6% during the 3rd quarter. Copeland Capital Management LLC now owns 11,889 shares of the medical technology company’s stock valued at $3,249,000 after buying an additional 1,694 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Price Performance

Shares of SYK opened at $338.97 on Tuesday. The company has a 50 day moving average of $348.68 and a two-hundred day moving average of $316.14. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $249.98 and a twelve month high of $361.41. The company has a market cap of $128.97 billion, a price-to-earnings ratio of 41.09, a price-to-earnings-growth ratio of 2.70 and a beta of 0.89.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share for the quarter, topping analysts’ consensus estimates of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The firm had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter last year, the firm earned $3.00 EPS. The business’s quarterly revenue was up 11.8% on a year-over-year basis. As a group, analysts predict that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a dividend of $0.80 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.94%. Stryker’s payout ratio is 38.79%.

Insider Activity

In related news, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the completion of the sale, the director now directly owns 3,755,128 shares in the company, valued at approximately $1,287,633,391.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Stryker news, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the sale, the director now owns 3,755,128 shares of the company’s stock, valued at approximately $1,287,633,391.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the sale, the director now owns 14,242 shares in the company, valued at approximately $4,856,522. The disclosure for this sale can be found here. Insiders have sold a total of 212,109 shares of company stock worth $72,845,768 over the last 90 days. 5.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Evercore ISI increased their price objective on Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. TD Cowen lifted their target price on Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Roth Mkm increased their price target on Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Finally, Royal Bank of Canada lifted their price objective on Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $340.67.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.